Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 18/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 17/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4207341 | 1.00 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL12510307 | 0.99 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL14253169 | 0.91 | CYP3A4 (0.67) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4203790 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4203784 | 0.91 | CYP3A4 (0.62) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4210984 | 0.90 | CYP3A4 (0.62) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL4210975 | 0.90 | CYP3A4 (0.62) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL14253363 | 0.88 | CYP3A4 (0.62) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2157426 | 0.87 | CYP3A4 (0.52) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2157435 | 0.87 | CYP3A4 (0.52) | CYP3A4CYP2C19CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149526-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-06-11 | — | — | US | claimed |
| US-20090149526-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-06-11 | — | — | US | disclosed |
| EP-1926733-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | Istituto di Ricerche di Biologia Molecolare P. Angeletti (IT) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007029029-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149526-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, ZC3HAV1, ZC3HAV1L | CYP3A4 234/4885CYP2C19 804/4885CYP2C9 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.